New hope for kids with severe arthritis: drug shows promise in reducing symptoms and steroid use

NCT ID NCT00339157

First seen Feb 20, 2026 · Last updated Jun 17, 2026 · Updated 19 times

Summary

This study tested a drug called anakinra in 24 children and young adults (ages 2-20) with severe systemic juvenile idiopathic arthritis that did not respond well to steroids. For the first month, half received anakinra and half received a placebo, then all received anakinra for 11 more months while slowly reducing steroids. The goal was to see if anakinra could improve arthritis symptoms and help patients use less steroids over a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Bordeaux CHU

    Bordeaux, 33000, France

  • Hopital Lyon Edouard Herriot

    Lyon, 69437, France

  • Kremlin-Bicetre Hospital

    Paris, 94270, France

  • Nancy Hopital d'Enfants

    Nancy, 54511, France

  • Pediatric Immuno-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, 149 rue de Sevres

    Paris, 75015, France

  • Robert Debre Hospital

    Paris, 75019, France

Conditions

The condition(s) this trial relates to.

juvenile idiopathic arthritis Rare Diseases systemic-onset juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.